Ending Soon! Save 33% on All Access

This Is Y Combinator's Next Hot Area of Investment For the first time, the accelerator program is actively recruiting startups outside the tech space.

By Laura Entis

Opinions expressed by Entrepreneur contributors are their own.

Until now, Y Combinator -- the prestigious accelerator program that vaulted some of Silicon Valley's most buzzed about companies, including Drobox, Airbnb and Reddit - was primarily a tech incubator.

But the accelerator is expanding its horizons. This year, for the very first time, it is pursuing health-tech startups, Reuters reported. "It's the right time for us to try health care," Sam Altman, Y Combinator's president, said, noting that there's been a recent and significant decrease in both "cost and cycle time."

Related: Google Wants to Build a Model of Perfect Human Health

While Altman conceded the move may unsettle venture capitalists, at least initially ("When we move into a new area, [they] usually don't like it," he said), it's not that big of a surprise. Venture capitalists across the country are suddenly pouring money into health technology companies. In 2013, according to the National Venture Capital Association, the biotechnology industry received 15.6 percent of all venture funding. Only the software industry, at 30.2 percent, took in a larger slice.

In addition, 2013 saw digital health startups, which include companies developing wearable tech and software/hardware solutions for specific diseases and conditions, take in almost $2 billion in funding, according to the venture fund Rock Health.

Related: 5 Startups to Watch at Y Combinator's Demo Day

While it was a record year for funding in the space, this year's funding total is going to blow last year's away: According Rock Health's 2014 mid-year report, the first half of 2014 saw digital health companies take in a whopping $2.2 billion.

Altman took over as president of Y Combinator when the accelerator's co-founder, Paul Graham, stepped down in February. On Tuesday, the first class of Y Combinator startups under Altman's tenure graduated from the program. They included a high percentage of health and biotech startups including The Immunity Project (a startup attempting to develop an HIV vaccine), Glowing Plant (which develops genetically engineered plants that function as air purifiers), UBiome (a startup that analyzes bacteria) and Ginko BioWorks (which is currently working to treat antibiotic resistant germs).

Related: 5 Questions Every Startup Should Ask Before Choosing an Incubator

Laura Entis is a reporter for Fortune.com's Venture section.

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Leadership

How a $10,000 Investment in AI Transformed My Career and Business Strategy

A bold $10,000 investment in AI and machine learning education fundamentally transformed my career and business strategy. Here's how adaption in the ever-evolving realm of AI — with the right investment in education, personal growth and business innovation — can transform your business.

Side Hustle

These Brothers Had 'No Income' When They Started a 'Low-Risk, High-Reward' Side Hustle to Chase a Big Dream — Now They've Surpassed $50 Million in Revenue

Sam Lewkowict, co-founder and CEO of men's grooming brand Black Wolf Nation, knows what it takes to harness the power of side gig for success.

Starting a Business

How to Find the Right Programmers: A Brief Guideline for Startup Founders

For startup founders under a plethora of challenges like timing, investors and changing market demand, it is extremely hard to hire programmers who can deliver.

Business Ideas

63 Small Business Ideas to Start in 2024

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2024.

Leadership

How to Break Free From the Cycle of Overthinking and Master Your Mind

Discover the true cost of negative thought loops — and practical strategies for nipping rumination in the bud.

Science & Technology

3 Major Mistakes Companies Are Making With AI That Is Limiting Their ROI

With so many competing narratives around the future of AI, it's no wonder companies are misaligned on the best approach for integrating it into their organizations.